Targets › EBNA3
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.
Open in Phaseline: the race on EBNA3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes Allogeneic EBV-specific T cells genetically modified to express CAR targeting CD19 | CD19, EBNA1, EBNA2, EBNA3 | Phase 1 | Acute Lymphocytic Leukemia | Sep 2027 |
Acute Lymphocytic Leukemia (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.